EA201190109A1 - ISOLATED POPULATIONS OF MONOCYTES AND RELATED THERAPEUTIC APPLICATIONS - Google Patents

ISOLATED POPULATIONS OF MONOCYTES AND RELATED THERAPEUTIC APPLICATIONS

Info

Publication number
EA201190109A1
EA201190109A1 EA201190109A EA201190109A EA201190109A1 EA 201190109 A1 EA201190109 A1 EA 201190109A1 EA 201190109 A EA201190109 A EA 201190109A EA 201190109 A EA201190109 A EA 201190109A EA 201190109 A1 EA201190109 A1 EA 201190109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monocytes
sample
isolated
red blood
blood cells
Prior art date
Application number
EA201190109A
Other languages
Russian (ru)
Inventor
Мартин Фридлэндер
Мэтью Р. Риттер
Стейси К. Морено
Мохаммед А. Эль-Калай
Original Assignee
Зе Скрипс Ресеч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Скрипс Ресеч Инститьют filed Critical Зе Скрипс Ресеч Инститьют
Publication of EA201190109A1 publication Critical patent/EA201190109A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/051—Lipid A (MPA, MPL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1497—Particle shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно настоящему изобретению предложены способы применения изолированных популяций моноцитов для лечения субъектов, страдающих от различных сосудистых заболеваний глаз или дегенеративных расстройств глаз. Согласно настоящему изобретению также предложены новые способы выделения, по существу, чистых популяций моноцитов. Указанные способы включают получение образца крови или образца костного мозга от субъекта, уменьшение количества красных кровяных клеток в указанном образце, а затем отделение оставшихся в образце красных кровяных клеток и других типов клеток от моноцитов. Вместо применения каких-либо селективных или вводящих метку агентов красные кровяные клетки и другие типы клеток отделяют от моноцитов на основании их размера, гранулярности или плотности. Изолированные моноциты можно дополнительно активировать in vitro или ex vivo перед введением субъекту. Согласно настоящему изобретению также предложены изолированные популяции клеток, содержащие, по существу, чистые моноциты CD14/CD33.According to the present invention, methods have been proposed for using isolated monocyte populations for treating subjects suffering from various vascular eye diseases or degenerative eye disorders. According to the present invention, new methods for isolating substantially pure monocyte populations are also proposed. These methods include obtaining a blood sample or bone marrow sample from the subject, reducing the number of red blood cells in the specified sample, and then separating the red blood cells remaining in the sample and other types of cells from monocytes. Instead of using any selective or labeling agents, red blood cells and other cell types are separated from monocytes based on their size, granularity, or density. Isolated monocytes can be further activated in vitro or ex vivo prior to administration to a subject. According to the present invention, isolated cell populations containing substantially pure CD14 / CD33 monocytes are also provided.

EA201190109A 2009-02-20 2010-02-19 ISOLATED POPULATIONS OF MONOCYTES AND RELATED THERAPEUTIC APPLICATIONS EA201190109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20817309P 2009-02-20 2009-02-20
US28324409P 2009-11-30 2009-11-30
PCT/US2010/000477 WO2010096177A1 (en) 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications

Publications (1)

Publication Number Publication Date
EA201190109A1 true EA201190109A1 (en) 2012-07-30

Family

ID=42634163

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190109A EA201190109A1 (en) 2009-02-20 2010-02-19 ISOLATED POPULATIONS OF MONOCYTES AND RELATED THERAPEUTIC APPLICATIONS

Country Status (11)

Country Link
EP (1) EP2398900A4 (en)
JP (1) JP2012518407A (en)
KR (1) KR20110123778A (en)
CN (1) CN102317446A (en)
AU (1) AU2010216374A1 (en)
BR (1) BRPI1008392A2 (en)
CA (1) CA2752679A1 (en)
EA (1) EA201190109A1 (en)
MX (1) MX2011008826A (en)
WO (1) WO2010096177A1 (en)
ZA (1) ZA201105869B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2999479B1 (en) * 2013-05-22 2021-01-06 Yeda Research and Development Co., Ltd. Human monocyte sub-population for treatment of eye diseases and disorders
KR101668462B1 (en) * 2015-02-26 2016-10-24 충북대학교 산학협력단 Pharmaceutical Composition for Preventing or Treating a Glaucoma Comprising Blood Components as Active Ingredients
FR3084463B1 (en) * 2018-07-30 2023-04-21 Francais Du Sang Ets METHOD FOR ANALYZING PLATELETS FROM A BLOOD SAMPLE
CN114441419B (en) * 2022-01-29 2022-11-22 杭州翔宇医学检验实验室有限公司 Flow type gate looping method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
EP1718735A1 (en) * 2004-02-11 2006-11-08 Aldagen, Inc. Stem cell populations and methods of use
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
EP2046366B1 (en) * 2006-06-28 2016-08-31 Yeda Research And Development Company Limited Copolymer-1 for treatment of age-related macular degeneration

Also Published As

Publication number Publication date
KR20110123778A (en) 2011-11-15
BRPI1008392A2 (en) 2015-08-25
CA2752679A1 (en) 2010-08-26
MX2011008826A (en) 2011-11-02
JP2012518407A (en) 2012-08-16
WO2010096177A1 (en) 2010-08-26
ZA201105869B (en) 2012-10-31
EP2398900A4 (en) 2012-08-22
EP2398900A1 (en) 2011-12-28
AU2010216374A1 (en) 2011-08-18
CN102317446A (en) 2012-01-11

Similar Documents

Publication Publication Date Title
Yin et al. Roles of extracellular vesicles in the aging microenvironment and age‐related diseases
Cicero et al. Extracellular vesicles shuffling intercellular messages: for good or for bad
Yeo et al. Exosome: a novel and safer therapeutic refinement of mesenchymal stem cell
Grisendi et al. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion
Ryu et al. Tonsil-derived mesenchymal stem cells alleviate concanavalin A-induced acute liver injury
Henao Agudelo et al. Mesenchymal stromal cell-derived microvesicles regulate an internal pro-inflammatory program in activated macrophages
Dong et al. Differential fates of tissue macrophages in the cochlea during postnatal development
Bruno et al. Role of extracellular vesicles in stem cell biology
EA201990583A1 (en) CELLULAR SUSPENSION FOR USE IN THE TREATMENT OF DISEASES OF PERIPHERAL ARTERIES OF THE LOWER EXTREMITIES
ITUB20155765A1 (en) Methods for diagnosis, prognosis and therapeutic monitoring of neurological, neurodegenerative and inflammatory pathologies based on microRNA contained in microglia microscopy
BR112012024350A2 (en) methods for treating patient by separating ctcs, capturing circulating tumor cells (ctc) in body fluid and discovering drugs, isolated ctcs, body fluid ctc capture filter and extracorporeal devices for capturing ctcs in body fluid
CN112795533A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
EP2171042B1 (en) T cell immunomodulation by placenta cell preparations
Mohammadi et al. Isolation and characterization of microvesicles from mesenchymal stem cells
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
EP3423070A1 (en) 3-d collagen scaffold-generated exosomes and uses thereof
EA201190109A1 (en) ISOLATED POPULATIONS OF MONOCYTES AND RELATED THERAPEUTIC APPLICATIONS
MX2010005863A (en) Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells.
Yang et al. Endometrial mesenchymal stem/stromal cell modulation of T cell proliferation
DE602005017812D1 (en) MULTIPOTENTIAL BLOOD CELLS FROM THE NAIL CORD AND CELL TREATMENT AGENT THEREFORE FOR THE TREATMENT OF ISCHEMIC ILLNESS
ES2609068B1 (en) METHOD FOR PRODUCING TOLEROGENIC DENDRITHIC CELLS WITH SPECIFIC ANTIGENS AND THEIR USES
Song et al. Superior therapeutic activity of TGF-β-induced extracellular vesicles against interstitial cystitis
Casadei et al. IMT504 blocks allodynia in rats with spared nerve injury by promoting the migration of mesenchymal stem cells and by favoring an anti-inflammatory milieu at the injured nerve
WO2020081859A1 (en) Mesenchymal stem cell derived exosomes and methods
KR20170043196A (en) Manufacturing method of therapeutic agent for alopecia containing stem cell constituent extract